CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen’s 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Leukemia panel date and time: Monday, March 4, 12:50 p.m. ET
Management will also participate in one-on-one meetings during the conference.
A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contacts:
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Adam Silverstein, ScientPR (Media)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Peter Kelleher, LifeSci Advisors (Investors)
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.47 |
| Daily Change: | -0.10 -2.80 |
| Daily Volume: | 60,309 |
| Market Cap: | US$192.900M |
April 15, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
